APTO-253 is a phase I clinical stage small molecule that selectively induces CDKN1A (p21), promotes G 0 -G 1 cell-cycle arrest, and triggers apoptosis in acute myeloid leukemia (AML) cells without producing myelosuppression in various animal species and humans. Differential gene expression analysis identified a pharmacodynamic effect on MYC expression, as well as induction of DNA repair and stress response pathways. APTO-253 was found to elicit a concentration-and time-dependent reduction in MYC mRNA expression and protein levels. Gene ontogeny and structural informatic analyses suggested a mechanism involving G-quadruplex (G4) stabilization. Intracellular pharmacokinetic studies in AML cells revealed that APTO-253 is converted intracellularly from a monomer to a ferrous complex [Fe (253) 3 ]. FRET assays demonstrated that both monomeric APTO-253 and Fe(253) 3 stabilize G4 structures from telomeres, MYC, and KIT promoters but do not bind to non-G4 doublestranded DNA. Although APTO-253 exerts a host of mechanistic sequelae, the effect of APTO-253 on MYC expression and its downstream target genes, on cell-cycle arrest, DNA damage, and stress responses can be explained by the action of Fe(253) 3 and APTO-253 on G-quadruplex DNA motifs.
Introduction
APTO-253, a small-molecule 2-indolyl imidazole [4,5-d] phenanthroline derivative, is currently undergoing clinical development for the treatment of acute myeloid leukemia (AML). It has broad in vitro cytotoxicity in various human tumor cell lines, including solid tumors, leukemias, and lymphomas (1) . APTO-253 has antitumor activity in murine xenograft models of the human solid tumors and was advanced into a phase I clinical trial in patients with advanced solid tumors (NCT123226; refs. [1] [2] [3] . In that solid tumor clinical trial, APTO-253 was well tolerated and produced evidence of antitumor activity in patients with advanced refractory solid tumors but did not produce myelosuppression even at the maximum tested dose. The most common treatment-emergent adverse effects of any grade were rash, peripheral neuropathy, hypersensitivity (<10%), and fatigue (>10%; ref. 4) . Recently, APTO-253 was tested for activity against primary cultures of leukemic mononuclear cells freshly isolated from 177 patients with hematologic malignancies through the BEAT AML Project (http://www.lls.org/beat-aml). Among the 80 AML patient samples tested, 43 (54%) were responsive to with an IC 50 <1 mmol/L (5). Because of its antitumor activity against AML cells, and because of its safety profile observed in the solid tumor clinical trial, APTO-253 was advanced into a phase I clinical trial in patients with relapsed/refractory hematologic malignancies (NCT02267863) with emphasis on AML.
The purpose of the current investigation was to gain a more complete understanding of the molecular mechanism through which APTO-253 kills AML cells. We report here that APTO-253 is associated with CDKN1A upregulation and MYC downregulation, followed by G 0 -G 1 cell-cycle arrest and apoptosis in AML cells. Moreover, inhibition of MYC, a well-recognized pivotal oncogene in AML, correlated with the cytotoxicity of APTO-253. Differential expression analysis suggested the involvement of DNA damage, including induction of g-H2AX accumulation, and cellular stress pathways after APTO-253 treatment. Prior cellular pharmacokinetic studies demonstrated that APTO-253 is transformed from a monomeric form to a ferrous complex [Fe (253) 3 ] in cells, and that this complex is the principal intracellular form of the drug (6) . In this study, we demonstrate that the parental APTO-253 and the Fe(253) 3 complex bind to and stabilize G-quadruplex (G4) motifs. The Fe(253) 3 complex stabilized G4 motifs found in the promoters of key oncogenes (e.g., MYC, KIT), as well as in rRNA genes and telomeres. This stabilization of secondary DNA structures was specific for G4 motifs, as the parental APTO-253 and Fe(253) 3 did not interact with ds-DNA. Treatment of MV4-11 AML cells with preformed Fe(253) 3 also inhibits MYC expression and induces CDKN1A expression along with induction of apoptotic and DNA damage pathways. Together, the results support the conclusion that the effect of APTO-253 on the expression of MYC and its downstream target genes, on cell-cycle arrest, and on DNA damage and stress responses can be linked to the action of APTO-253 and the Fe (253) 3 on G-quadruplex DNA motifs.
Materials and Methods

Cells and compounds
EOL-1, GRANTA-519, Jeko-1, Jurkat, Molm-13, NOMO-1, SKM-1, and SU-DHL-6 were obtained from Leibniz-Institut DSMZ. HL-60, KG-1, Mino, MV4-11, Raji, and THP-1 were obtained from ATCC. HEL92.1.7 were obtained from the European Collection of Authenticated Cell Cultures and Ramos cells were a gift from Dr. M. Andreeff (MD Anderson Cancer Center, Houston, TX). All cells were cultured in complete media as per the manufacturer's instructions. Early passage cells were collected and frozen within 1 month of receipt from the manufacturer. All experiments were performed on early passage cells within 6 weeks of thawing. MycoScope Mycoplasma Detection Kit (Genlantis catalog # MY01050) was used to screen for potential contamination every 6 months. Peripheral blood mononuclear cells (PBMC) were isolated from fresh healthy donor blood using Ficoll-Paque PLUS (GE Healthcare, catalog #17-1440-02). For synthesis of APTO-253 free base, 10-phenanthroline-5,6-dione (1.2 equivalents), acetic acid (22 volumes), 2-methyl-5-fluoroindole-3-carboxaldehyde (1.0 equivalents), and ammonium acetate (15 equivalents) were reacted under medium agitation while heated at 95 AE 5 C for 3 to 7 hours. The reaction was cooled to between 20 C and 25 C, filtered, rinsed with acetic acid and ethanol, and dried with N 2 purge, followed by a wash with 2:1 ethanol: water at 65 C for 4 hours, cooling to 20 C to 25 C, filtration, rinsing with 2:1 ethanol:water and EtOAc, and then dried with N 2 purge. The purity by HPLC was 99.5%, and the structural identity was confirmed by FT-IR, 1 HNMR, 13 C NMR, and LC/MS. For Fe(253) 3 synthesis, five molar equivalents of ferrous ion FeS0 4 in water was added to APTO-253 dissolved in ethanol. The deep red precipitate produced, Fe(253) 3 , was collected and dissolved in DMSO and characterized by HPLC and mass spectrometry as >95% pure. CX-5461 (7) was purchased from MedChem Express (catalog # HY-13323).
Cytotoxicity study
Cells were plated and treated with vehicle DMSO or APTO-253 (10 concentrations) in 96-well plates for 5 days at 37 C and 5% CO 2 . Cell viability was measured using CellTiter 96 AQ ueous one solution (MTS) cell proliferation assay (Promega, catalog #G3581), and IC 50 values were calculated using GraphPad Prism 7 software.
Uptake and efflux assay
Cells exposed to APTO-253 were homogenized in acetonitrile containing 5 ng of deuterated APTO-253 standard. Samples were analyzed at the UCSD Molecular Mass Spectrometry Facility employing an Agilent 1260 liquid chromatograph (LC) system coupled with a Thermo LCQdeca mass spectrometer using positive ion mode electrospray ionization as the ion source.
qRT-PCR
Cells were treated with vehicle or APTO-253 at various concentrations for 24 hours or at a single concentration for 1, 3, 6, 12, and 24 hours before harvesting. Cells were lysed by QiaShredder columns (QIAGEN, catalog # 79656), total RNA was isolated using QIAGEN RNeasy Plus Mini Kit (catalog # 74134), and cDNA was synthesized utilizing Transcriptor Universal cDNA master mix (Roche, catalog # 05893151001) and then used for qRT-PCR analysis using FastStart essential DNA probes master mix (Roche, catalog # 06402682001) and Roche LightCycler96. Primer probe pairs were purchased from IDT (Supplementary  Table S1 ). Expression was calculated as fold change over vehicle treated samples after normalizing to GAPDH (2 DDC t ).
Western blotting
Cells were treated as described above. Whole-cell lysates were prepared, separated by SDS-PAGE, and transferred to nitrocellulose membranes. Detection antibodies used are listed in Supplementary Table S2 . Densitometry was performed using ImageJ or Image Studio Lite Version5.2 software and normalized to the density of GAPDH.
Flow cytometry for apoptosis and cell-cycle analysis Cells were treated as described above. To determine apoptosis, cells were stained with FITC-Annexin V and propidium iodide (PI; BD Pharmingen, catalog #556570) and then analyzed on BD Accuri C6 flow cytometer. To measure DNA synthesis and phases of cell cycle, treated cells were stained with 5-ethynyl-2 0 -deoxyuridine (Edu) Alexa Fluor 488 (Thermo Fisher Scientific, catalog #C10425) and PI (PI/RNase A staining solution, BD Biosciences, catalog #550825). The dead cells were excluded from analysis by using Live/Dead Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific, catalog # L34973). Staining was performed as per the manufacturers' instructions.
RNA sequencing analysis
Treated MV4-11 cells were subjected to total RNA extraction (as for qRT-PCR analysis) and sequenced at the UCSD genomics core facility. RNA was processed using Illumina TruSeq and single end sequenced for 50-bp reads on the Illumina HiSeq4000. Data were analyzed by the McWeeny lab at Oregon Health and Science University (Portland, OR). FASTQ files were assessed for read base distribution and sequence representation using FASTQC http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Reads were aligned to HG37 using SubRead v1.5.0-pl keeping uniquely mapped reads (8) . Differential expression genes with less than 50 reads (across all 4 samples) were discarded. Raw data and processed files are available on GEO (https://www.ncbi.nlm. nih.gov/geo/query/acc.cgi?acc¼GSE111949) accession number GSE111949.
Reverse-phase protein array analysis MV4-11 cells were treated as for RNA sequencing (RNA-seq) analysis and whole-cell extracts were prepared for Western blotting. Samples were processed at MD Anderson Cancer Center reverse-phase protein array (RPPA) core facility (details at https:// www.mdanderson.org/research/research-resources/core-facili ties/functional-proteomics-rppa-core/rppa-process.html). Protein expression levels were averaged for 3 replicates and heatmaps were drawn using GraphPad Prism 7.
Chromatin immunoprecipitation coupled with qPCR MV4-11 cells were treated with vehicle DMSO or 500 nmol/L APTO-253 for 2, 6, or 24 hours and then crosslinked with 1% formaldehyde. Chromatin was extracted by sonication and then incubated with H3K27ac (Active Motif #39133) antibody overnight. The antibody:DNA complexes were isolated with Protein G beads (Invitrogen Dynabeads catalog #10004D) and analyzed by qPCR with primers specific to the MYC promoter (Supplementary Table S3 ). H3K27ac enrichment was calculated as fold over input DNA control.
RNA decay assay
Cells were treated for 3 hours with vehicle DMSO or 500 nmol/ L APTO-253 followed by 1 mmol/L actinomycin D. Aliquots of cells were taken before and then every 10 minutes after actinomycin D addition for RNA extraction and cDNA synthesis as for qRT-PCR analysis. Levels of MYC and 28s rRNA were analyzed using specific primers (Supplementary Table S4 ) and MYC RNA expression was normalized to 28s rRNA [2^(28s C t value -MYC C t value)].
FRET assay
FRET assay and data analysis was performed as described previously (9, 10) and modified by using dual labeled (5 0 FAM -3 0 BHQ1) single-stranded oligos. Melting temperature of each oligo was assessed in the presence of vehicle DMSO or escalating concentrations of APTO-253, Fe(253) 3, CX-5461, or TMPyP4 using a Roche LightCycler 96 [at 37 C for 300 seconds followed by temperature increased in 3 C intervals up to 91 C (25 steps) with 300-second total incubation time at each temperature]. Drug and oligo reaction mixes were analyzed immediately or incubated for 6 hours at room temperature and then analyzed. Primer information is provided in Supplementary Table S5 . Longer incubation time did not affect Fe (253) S1B and S1C). The upregulation of CDKN1A mRNA increased with duration of exposure in all AML cell lines tested (Supplementary Fig. S1D and S1E). At later time points, CDKN1A expression began to decrease, likely due to increasing cell death. Induction of CDKN1A expression is typically associated with a subsequent G 0 -G 1 cell-cycle arrest, which was observed following APTO-253 treatment of solid tumor lines (1, 12, 13) . Consistent with this, we observed a dose-dependent increase of cells in G 0 -G 1 with concomitant reduction in the fraction of cells in the S-and G 2 -M phases for all AML cell lines tested ( Fig. 2A-C, top) . In the case of MV4-11, all live cells had arrested in G 0 -G 1 after 24-hour exposure to 1 mmol/L APTO-253. CCND3 (Cyclin D3) and CDK4 are known to promote G 1 cell-cycle progression, while CDKN1A serves to negatively regulate this process. Western blot analysis of APTO-253-treated AML cells revealed dose-dependent inhibition of both CDK4 and CCND3, albeit to different degrees in each of the 3 AML lines ( Fig. 2A -C, bottom; Supplementary Fig. S2A ).
To correlate cell-cycle arrest with various pathway perturbations, and to delineate the sequence of mechanistic events, cellcycle analyses were performed after treating cells with either vehicle or APTO-253 (IC 50 concentration) for various times up to 24 hours. There was no perturbation of cell-cycle phase distribution in cells treated with vehicle alone. An increase in the fraction of cells in G 0 -G 1 was detected as early as 2 hours, and this fraction continued to increase in a time-dependent manner throughout the 24-hour period of drug exposure ( Fig. 2D-F) . Western blot analysis showed a time-dependent decrease of CDK4 and CCND3 protein levels that paralleled the G 0 -G 1 arrest ( Supplementary Fig. S2B and S2C ). These data establish that APTO-253 produces a time-and concentrationdependent G 0 -G 1 arrest in AML cells and suggest that this is mediated by established p21 and cyclin-dependent kinase pathways.
APTO-253 induces apoptosis in AML cell lines
To investigate the mechanism by which APTO-253 causes cell death, MV4-11, EOL-1, and KG-1 AML cells were treated with or without APTO-253 and subjected to apoptotic marker detection by flow cytometry and Western blotting. Cells were stained with PI and Annexin V to distinguish between live (Annexin V and PI negative), early apoptotic (Annexin V positive and PI negative), late apoptotic (Annexin V and PI positive), and dead (Annexin V negative and PI positive) cells. A concentration-dependent increase in apoptotic cells was observed at 24 hours in all cell lines ( Fig. 3A; Supplementary Fig. S3A) Fig. S3B ). For all 3 AML cell lines, increases in apoptotic cells appeared between 3 and 6 hours after exposure to APTO-253 (Fig. 3D) , which followed G 0 -G 1 cell-cycle arrest observed at 2-hour exposure.
APTO-253 pharmacodynamics
To gain further insight into the pathways exploited by APTO-253 to cause cell-cycle arrest and apoptosis, we performed differential expression analysis at both the mRNA and protein levels. MV4-11 cells were treated with either vehicle or 500 nmol/L APTO-253 for 6 hours, and then gene expression was analyzed by RNA-seq. A total of 1,643 genes were found to be differentially regulated upon APTO-253 treatment (>2-fold change and P < 0.05) with 416 being upregulated and 1,227 being downregulated (Supplementary Table S7 ). The RNA-seq analysis detected a 2-fold increase in KLF4 and a 4.5-fold increase in CDKN1A expression, which is validated by the qRT-PCR data with MV4-11 cells. The differentially regulated genes were analyzed for enriched pathways or GO (Gene Ontology) terms ( Supplementary Fig. S4A ) utilizing the Broad Molecular Signatures database (http://software.broadinstitute. org/gsea/msigdb/index.jsp). As expected, apoptotic and cellcycle pathways were enriched in the differentially expressed gene set. Unexpectedly, gene expression profiles after APTO-253 treatment were also enriched in the DNA damage response (DDR) and endoplasmic reticulum (ER) stress/unfolded protein response pathways. In addition, upregulated genes were enriched in TP53 pathways and genes downregulated by MYC. Gene expression changes detected in MV4-11 cells raised the possibility that APTO-253 could cause apoptosis by inducing DNA damage and activating cellular stress pathways, and/or by inhibition of expression of the MYC oncogene.
To examine the effect of APTO-253 on protein expression, MV4-11 cells were treated as above and analyzed by RPPA microarray to quantify >300 total and posttranslationally modified proteins. Effects were observed on levels of both total and posttranslationally modified proteins (>1.25-fold and Table S7 ). Of note, there was an increase of cleaved caspase-7, which is indicative of apoptosis. GO analysis of the differentially expressed proteins was performed utilizing the Broad Molecular Signatures database. Significant GO terms included cell death and G 1 -S cell-cycle arrest pathways, a formal description of G 0 -G 1 arrest, and consistent with the cell-cycle effects detected by flow cytometry and the RNA-seq analyses (Supplementary Fig.  S4C ). An increase in E2F1, TP53, gH2AX, CHEK1 phos-S296, and CHEK2 phos-T68 supported the concept that DNA damage pathways are triggered by APTO-253 treatment (14) . In addition, increases in XBP1, HSPA5, and MAPK14 (p38) phos-T180/182 were observed, indicating ER or cellular stress (P ¼ 1.89E À08 ; ref. 15) . DDR pathways can also signal through the MAPK pathway activating MAPK14 and MAPK8 (JNK), and cross-talk between the DDR pathway and ER stress is a wellestablished phenomenon (14) although it is unclear which pathway represents the initiating event. A significant portion of the differentially expressed proteins and mRNAs are target genes of MYC oncoprotein, which is known to be an integral part of both cell-cycle and apoptotic pathway regulation. Collectively, these data suggested that regulation of the MYC oncogene may play an early and key role in the mechanism of APTO-253.
APTO-253 concentration-and time dependently downregulates MYC mRNA and protein levels in AML cells
MYC expression is implicated in the pathogenesis of a wide range of cancers, including leukemia and lymphoma (16) . A recent study demonstrated that inhibition of MYC transcription leads to apoptosis in cancer cells of hematologic origin, making MYC an attractive therapeutic target (17, 18) . A review of our RNAseq dataset revealed that MYC was downregulated by APTO-253 in MV4-11 cells at 6 hours. We also observed increased transcription of genes negatively regulated by MYC in APTO-253-treated MV4-11 cells. APTO-253 produced a concentration-dependent decrease in both MYC mRNA and protein levels in all AML cell lines tested, and the IC 50 values for MYC inhibition paralleled the antiproliferative IC 50 values ( Fig. 4A and B) . These changes increased as a function of exposure time up to 24 hours in the MV4-11, EOL-1, and KG-1 AML cells ( Fig. 4C ; Supplementary  Fig. S5A and S5B) . The time course of MYC protein repression in MV4-11 cells paralleled inhibition of MYC gene expression levels detected by RNA-seq. All the tested AML cell lines had significantly higher basal expression of MYC as compared with PBMCs from healthy donors ( Fig. 4D; Supplementary Fig. S5C ). Thus, APTO-253 downregulates MYC at the mRNA and protein level in all AML cell lines examined.
Regulation of MYC expression is a complex process that involves MYC transcription, mRNA stability, and protein turnover (19) . ChIP-qPCR analysis for H3K27ac, a well-established marker of active chromatin, was performed to assess transcriptional competency of the MYC gene promoter after treatment with APTO-253 ( Supplementary Fig. S5D ). A decrease in H3K27ac at the MYC promoter in MV4-11 cells was observed as early as 2 hours and progressed over time, indicating that modification of the MYC promoter and subsequent transcriptional repression of the MYC gene is an early mediator of the APTO-253 mechanism of action ( Supplementary Fig. S5E ). To determine whether Fig. S5F ), indicating that APTO-253 can decrease the stability of MYC mRNA. These data suggest that APTO-253 regulates MYC by affecting both transcription and mRNA stability.
APTO-253 triggers DNA damage and cellular stress pathways
In addition to MYC, RNA and protein differential expression analyses pointed to the involvement of TP53, DNA damage, and ER stress in the mechanism of action of APTO-253. We sought to validate the RPPA data that had demonstrated an increase in TP53 protein level after APTO-253 treatment in MV4-11 cells. Exposure of MV4-11 cells to 500 nmol/L APTO-253 produced a significant increase in TP53 levels at early time points (1, 3, and 6 hours), followed by a return to baseline at 12 hours and a further reduction at 24 hours, presumably due to extensive cell death at this time point (Fig. 5A) . The increase in total protein was concomitant with an increase in phospho-Ser15 and acetyl-K382 (Fig. 5B) . TP53 is phosphorylated at Ser15 and Ser20 in response to DNA damage, which reduces MDM2 binding and proteasomal degradation of p53 (20) . Furthermore, p53 is acetylated in response to cellular stress, and this modification can further stabilize TP53 protein levels and modulate binding activity (21) . Activation of TP53 can trigger apoptosis through upregulation of proapoptotic factors such as BBC3 (PUMA), PMAIP1 (NOXA), and BAX (22) . The RNA-seq dataset showed a 3.95-fold increase in BBC3 and 1.38-fold increase in PMAIP1 in APTO-253-treated MV4-11 cells. Involvement of DNA damage and cell stress pathways was further interrogated in MV4-11 cells at early time points after treatment with 500 nmol/L APTO-253. An increase in phos-CHEK1 was detected at 1 hour after APTO-253 addition with a peak at approximately 4 hours, suggesting that DNA damage was an early event (Fig. 5C) . Following CHEK1 phosphorylation, there was a robust increase in the DDR marker gH2AX by 6 hours. A concentration-dependent increase in gH2AX was detected in all AML lines tested, thereby adding further credence to the concept that APTO-253 triggers the DDR pathway (Fig. 5D ). In addition, there was an increase in both MAPK14 phos-T180 and MAPK8 phos-Thr183/pTyr185 at 4-to 6-hour treatment, which indicated signaling through the DDR or ER stress pathways (Fig. 5C) . Overall, the data suggest that DNA damage induced by APTO-253 is an early event in the mechanism of APTO-253.
Intracellular pharmacokinetics of APTO-253
Measurement of the kinetics of uptake and efflux of APTO-253 in KG-1 AML cells determined by mass spectrometry indicated a gradual approach to steady state and a rapid initial efflux, but a very prolonged terminal efflux ( Supplementary Fig. S6A and S6B ). When KG-1 cells were exposed to APTO-253 for either 1 or 6 hours and then placed in drug-free media, the efflux pattern consisted of a rapid phase occurring during the first 30 minutes followed by a prolonged terminal phase, such that significant amounts of APTO-253 were retained in KG-1 cells for longer than 24 hours. Consistent with these data, cellular pharmacokinetic studies disclosed that APTO-253 is transformed intracellularly to a complex containing 1 atom of Fe and 3 molecules of 253 [Fe(253) 3 ] (Supplementary Fig. S6C and S6D; ref. 6) . Indeed, the precomplexed Fe(253) 3 drug is as potent as the parental APTO-253 monomer in cytotoxicity assays (Fig. 6A) . Furthermore, Fe (253) 3 complex triggered apoptotic and DNA damage pathways, as measured by c-PARP and gH2AX respectively, in MV-4-11 cells. Fe(253) 3 also induced KLF4 and CDKN1A expression and inhibited MYC in a dose-dependent manner (Fig. 6B) . However, higher 
APTO-253 stabilizes G-quadruplex sequences
The parental APTO-253 and its intracellular Fe(253) 3 form contain certain features, such as metal-coordinating phenanthroline rings and planar structures, that may allow the agent to function as a G-quadruplex (G4) DNA ligand (23, 24) . G4 is a dynamic secondary DNA structure caused by guanine-rich regions folding to form planar guanine tetrads, which stack on top of one another (25) . G4-specific sequences are found at telomeres and in the promoters of many important oncogenes (26) . G4 sequences serve as regulators of gene expression and small-molecule ligands that stabilize G4 quadruplexes have been exploited to downregulate important oncogenes, such as KIT and MYC (27, 28) . Stabilization of G4 motifs in telomere DNA can cause inhibition of telomerase, telomere instability, and deprotection, all of which can trigger DDR pathways (29) . Furthermore, origin of DNA replication sites overlap with DNA G4 sequences, and stabilization of G-quadruplex structures at such sites causes stalling of replication forks and cell-cycle arrest (30) .
We evaluated the ability of APTO-253 (parental monomeric form of the drug) and Fe(253) 3 to bind and stabilize G4 sequences using a modified FRET assay ( Supplementary Figs. S7 and S8 ). TMPyP4, a well-known G4 ligand, and CX-5461, a clinical stage molecule recently reported to have G4-binding properties, were utilized as controls to assess the specificity of APTO-253 and Fe (253) 3 for G4-stabilizing activity (25, 31) . As expected, CX-5461 was a potent stabilizer of all G4 sequences tested, and TMPyP4 stabilized all G4 motifs except the G4 of the KIT gene promoter (Fig. 6C) . Interestingly, increasing concentrations of Fe(253) 3 stabilized the G4 structures corresponding to the MYC and KIT gene promoters, rRNA, and telomeres with a similar potency to TMPyP4 ( Fig. 6C; Supplementary Fig. S8 ). Parental monomeric APTO-253 also showed time-dependent stabilization of G4 motifs, but it demonstrated the greatest propensity for stabilizing the MYC G4 sequences (Fig. 6C) .
To assess selectivity for G4 structures over nonspecific interactions with ds-DNA, the FRET assay was repeated with a selfcomplimentary oligo that forms a ds-DNA hairpin in solution. Notably, Fe(253) 3 demonstrated a much higher degree of selectivity for G4 structures over ds-DNA than did both CX-5461 and TMPyP4, highlighting the fact that APTO-253 is a more discriminating G4 ligand ( Fig. 6C; Supplementary Fig. S7B ). Gene expression analyses showed that the expression of MYC and KIT was decreased in AML cells in response to APTO-253 treatment (RNA-seq data, MV4-11 cells 6-hour treatment), but levels of 45s rRNA were not. The lack of effect on 45s rRNA may reflect differences in availability of APTO-253 and/or Fe(253)3 into the rRNA-rich nucleolar region of the nucleus. Nevertheless, APTO-253 clearly can stabilize G4 structures, which provides an explanation for the inhibition of the expression of MYC and other genes. We hypothesize that stabilization of G4 motifs by APTO-253 results in single-and double-strand breaks at replication forks and telomeres; this G4-binding capacity of APTO-253 identifies a mechanism by which the drug triggers DDR pathways, cell-cycle arrest, and apoptosis.
Discussion
APTO-253 is currently in clinical development for the treatment of AML because of its efficacy in nonclinical models and the fact that it did not produce myelosuppression in animals or in its initial phase I trial in solid tumor patients (1, 4) . The data reported here provide new insights into the mechanism of action of this novel agent that point the way to more precise clinical application and biomarker development. These studies confirmed that APTO-253 is a potent inducer of G 0 -G 1 cell-cycle arrest and apoptosis in AML cells. Additional new findings include that APTO-253 produces time-and concentration-dependent downregulation of MYC through effects on both its promoters and mRNA stability, that in many AML cell lines it induces the master transcription factor and tumor suppressor KLF4, and that it induces DNA damage. In addition, the precomplexed iron form of APTO-253, Fe(253) 3 , causes comparable cytotoxic cellular effects, including apoptosis, DNA damage, and downregulation of MYC expression. The discovery that ATPO-253, whether in its parental monomeric form or the Fe(253) 3 iron complex form, stabilizes G4 motifs in DNA provides an explanation for many of the pharmacodynamic effects of this drug. Stabilization of G4s is known to disrupt telomere stability and stall replication forks, resulting in single-and double-strand DNA breaks (29, 30) . Such stabilization of G4 in the MYC promoter is thought to function as a gene silencer. This, coupled with targeting of KIT and telomere G4 structures by APTO-253, provides a mechanism through which APTO-253 activates DDR pathways that coordinate cell-cycle arrest and promote apoptosis in AML cells. In addition, cells harboring BRCA1/2 mutations are hypersensitive to APTO-253, further supporting a role for DNA damage in APTO-253 mechanism of action. APTO-253 consistently produced upregulation of CDKN1A, which mediates arrest in G 0 -G 1 (13) . In addition, CDKN1A can be induced after DNA double-strand breaks to block cell-cycle progression to allow for sufficient time to repair DNA (32) . In combination with CDKN1A induction, APTO-253 increased KLF4 gene expression in many AML cell lines, which is known to regulate CDKN1A as part of the G 1 cell-cycle checkpoint (33) . KLF4 is also known to be upregulated in response to DNA damage and plays a role in both G 0 -G 1 arrest and apoptosis (34, 35) . The role of KLF4 in APTO-253 mechanism of action is of interest for future studies. Although the structure of APTO-253 suggests that it might be able to generate reactive oxygen species, no such species have been detected using either molecular sensors or changes in GSH in MV4-11, EOL1, or KG-1 cells. Activation of CHEK1/2, stabilization of TP53, and induction of E2F1 also indicate that the early events after APTO-253 treatment function to signal for cell-cycle arrest and DNA repair (21) (22) (23) 25) . Cell-cycle arrest was detected by 2 hours after APTO-253 treatment, whereas upregulation of several proapoptotic factors at both the RNA and protein levels was observed by 6 hours. In addition to activating DNA repair processes, pCHEK1/2 and TP53 can also play a role in triggering apoptosis. If DNA repair fails, p53 can activate apoptosis via upregulation of BAX, BAD, BBC3, or PMAIP1 (22) . Increased expression of these proapoptotic factors was detected by RNA-seq analysis of APTO-253-treated MV4-11 cells. It is known that caspase-dependent cleavage of PARP1 is required for apoptosis to proceed. APTO-253 produced robust and early PARP1 cleavage, adding further credence to the hypothesis that APTO-253 functions by triggering DDR pathways. This suggests a level of DNA damage that is catastrophic to the cell and an alteration of transcriptional programs that skew the cell toward apoptosis.
MYC dysregulation is a common oncogenic driver in multiple malignancies, which makes it an attractive potential therapeutic target. However, targeting MYC is challenging due to the complexity of MYC regulation and signaling. Recently, repression of MYC expression by BET bromodomain inhibitors has proven effective at triggering apoptosis in leukemia cells (18) . However, bromodomain proteins are present on all active genes, and inhibition of bromodomain proteins can cause severe toxicities and myelosuppression. APTO-253 produced a decrease in MYC expression at both the RNA and protein levels in all AML cell lines tested, and downregulation of MYC paralleled its cytotoxic potency in different AML cells. We detected higher MYC levels in AML lines than in PBMCs from healthy donors, which may be linked to the differential effect of APTO-253 on these types of cells. Recent work demonstrated that coordinated upregulation of TP53 and downregulation of MYC led to efficient clearing of leukemic stem cell populations in CML (36) . APTO-253 treatment of MV4-11 produced this same effect, which provides an additional rationale for its development. It has been reported that higher MYC expression correlates with a poor clinical outcome in epithelial ovarian cancer and neuroblastoma, suggesting that APTO-253 may have a beneficial effect against these malignancies (37) . Collectively, our data demonstrate a multifaceted mechanism of action for APTO-253, primarily through engagement of G-quadruplex structures, that is uniquely suited to targeting hematopoietic malignancies. Moreover, APTO-253 represents a first-in-class MYC inhibitor that does not cause myelosuppression, making it particularly appropriate for the management of AML patients with compromised bone marrow function.
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